Immix Biopharma Past Earnings Performance
Past criteria checks 0/6
Immix Biopharma's earnings have been declining at an average annual rate of -31.9%, while the Biotechs industry saw earnings growing at 15% annually.
Key information
-31.9%
Earnings growth rate
-0.05%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -66.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
May 21Revenue & Expenses Breakdown
How Immix Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -18 | 9 | 11 |
| 31 Dec 23 | 0 | -15 | 7 | 9 |
| 30 Sep 23 | 0 | -14 | 7 | 8 |
| 30 Jun 23 | 0 | -11 | 5 | 6 |
| 31 Mar 23 | 0 | -9 | 5 | 5 |
| 31 Dec 22 | 0 | -8 | 4 | 4 |
| 30 Sep 22 | 0 | -27 | 3 | 2 |
| 30 Jun 22 | 0 | -26 | 3 | 1 |
| 31 Mar 22 | 0 | -25 | 2 | 1 |
| 31 Dec 21 | 0 | -24 | 1 | 0 |
| 30 Sep 21 | 0 | -2 | 1 | 0 |
| 30 Jun 21 | 0 | -2 | 0 | 0 |
| 31 Mar 21 | 0 | -2 | 0 | 0 |
| 31 Dec 20 | 0 | -1 | 0 | 0 |
Quality Earnings: IMMX is currently unprofitable.
Growing Profit Margin: IMMX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMMX is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare IMMX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: IMMX has a negative Return on Equity (-66.69%), as it is currently unprofitable.